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Immunological manifestation occasionally develops concurrently with lymphoid neoplasms, including
immune thrombocytopenia and autoimmune hemolytic anemia, but rarely reported acquired aplastic
anemia (AA). Here we present a female case of diffuse large B cell lymphoma (DLBCL) with antecedent
presentation of AA. Recovery of AA was noted after complete response to lymphoma treatment. Liter-
ature regarding this issue was reviewed.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acquired aplastic anemia (AA) is an idiopathic disease man-
ifested as unexplained bonemarrow hypocellularity and peripheral
cytopenia. Clinical response to immuno-suppressive therapy (IST)1
and HLA-DR15 restriction2,3 manner both support an immune
pathogenesis of idiopathic AA. It is caused by T-cell mediated
autoimmune response against immature HLA-DR (þ) hematopoi-
etic progenitor cells. Rising evidence has shown that AA can also be
a para-neoplastic phenomenon of lymphoid neoplasms.2,4,5
Lymphoid neoplasms may precede AA, or occur concomitantly or
metachronously with AA. While some cases with AA and lym-
phoma can be para-neoplastic AA, some others may also be treat-
ment related. Physicians might have dilemma in treating
simultaneous AA and lymphoid neoplasms.5,6 For example, what is
the aim of therapy? Would the marrow hematopoiesis recover or
get worse after chemotherapy for lymphoid neoplasms? Here we
present a female case of diffuse large B cell lymphoma (DLBCL) with
antecedent presentation of AA. Recovery of AA was noted aftery, Department of Internal
ec. 2, Shipai Rd., Beitou Dis-
en).
ncology Society.
y Society. Production and hosting
).complete response to lymphoma treatment. We also reviewed the
literature regarding this issue.
2. Case report
A 50-year-old female presented with splenomegaly (24 cm) and
pancytopenia in Mar. 2014. A bone marrow biopsy revealed hypo-
cellular marrow (<5%). Biochemistry tests including ANA and anti-
Ds-DNA were normal. Flow cytometry revealed no CD59/CD55
deﬁcient clones. Aplastic anemia was diagnosed after serial work-
ups. She initially received low dose prednisolone (10 mg/day).
The hemogram improved but worsened again in Dec. 2014. On
examinations showed white cell count (WBC) 810/ul; hemoglobin
7.0 g/dl; platelet count 64,000/ul, and lactate dehydrogenase
1041 U/L. An abdominal computed tomography revealed extensive
lymphadenopathies mainly at retroperitoneum and massive
splenomegaly, with biopsy proved DLBCL (Fig. 1).
Repeated bone marrow biopsy again showed remarkable
hypocellularity (Fig. 2). Concerning for profound myelosup-
pression, we delivered chemotherapy with standard dose R-COP
regimen (rituximab; cyclophosphamide; vincistine, and oral pred-
nisolone), and we skipped anthracycline for the ﬁrst 3 cycles due to
concern for profound marrow suppression. Long-acting ﬁlgrastim
(pegylated granulocyte colony stimulating factor, [G-CSF]) was
given 24 h after chemotherapy. The patient stood 3 cycles of R-COP
very well and there was no occurrence of neutropenia. Interest-
ingly, her WBC recovered shortly after the 1st cycle of R-COPby Elsevier B.V. This is an open access article under the CC BY-NC-ND license
Fig. 1. (A) DLBCL diagnosed 9 months after diagnosis of aplastic anemia (HE stain, 1000X). (B) Strong CD20 positive (IHC stain for CD20, 1000X). (C) Massive splenomegaly at
diagnosis by abdominal CT.
Fig. 2. (A) Hypocellular marrow at initial presentation and (B) at diagnosis of DLBCL 9 months later, neither marrow involvement (both HE stain, 200X).
Fig. 3. Trends of white blood cell and platelet counts: transient response after IST usage but rapid recovery of hematopoiesis after 1st cycle of cytotoxic therapy.
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CEOP (rituximab; cyclophosphamide; epirubicin; vincistine, and
oral prednisolone) regimen were given, and a follow-up abdomen
CT showed marked decreased spleen size and resolution of previ-
ous lymphadenopathy (Fig. 4). PET-CT conﬁrmed complete meta-
bolic response (Fig. 5). We accomplished successful stem cell
harvest after documented recovery of hematopoiesis (Fig. 6). Her
HLA-DR typing revealed DRB1*12.3. Discussion
Immunological manifestations occasionally develop concur-
rently with lymphoid neoplasms, including immune thrombocy-
topenia and autoimmune hemolytic anemia, but rarely acquired
AA. Since Keisu et al notiﬁed one third of patients with initial
diagnosis of acquired idiopathic AA developed myelodysplastic
syndrome (MDS) or Non-Hodgkin lymphoma (NHL),7 there have
been more and more studies ﬁnding chronological associations
between AA and NHL: some cases developed NHL during IST for
initially diagnosed AA.8e11 In literature review, NHL tends to occur
shortly after IST for antecedent AA, predominantly 2e4 months
Fig. 4. Spleen involvement and lymphadenopathy at diagnosis of DLBCL (A); remarkable remission after 6 cycles of chemotherapy (B).
Fig. 5. Complete metabolic response by PET-CT.
Fig. 6. Recovery of hematopoiesis after complete remission of lymphoma, obtained
before stem cell harvest (HE stain, 200X).
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withdrawal of IST plus radiotherapy attain complete remission.
Suzuki et al13 used anthracycline-based chemotherapy to achieve a
partial remission; while Saitoh et al reported a case that followed amore fulminant course and showed no response to IST withdrawal
or chemotherapy, which might be the nature of a late stage re-
lapsing lymphoma.12 On the other hand, NHL could also developed
after a protracted use of IST, often 1.5 years later, in which T-cell14,15
or B-cell13,16 neoplasms evolved equally, and responded poorly to
chemotherapy, carrying a grim prognosis.
HLA-DR15 might account for the paraneoplastic relationship
between lymphoproliferative disease (LPD) and preceding AA:
Nissen et al reported a case of NHL with tumor regression
completely 10 days after diagnosis, accompanied with progressive
pancytopenia, without treatment. The patient was positive for HLA-
DR152; Jerez et al found a higher frequency of HLA-DR15 positivity
(75% vs 44%, P ¼ 0.02) in patient with concomitant AA and T large
granular lymphocyte leukemia (T-LGL) than those who had no T-
LGL clone.4 Though it is not HLA-DR15 in our case, whether other
immunogenic HLA subtypes could predispose to both AA and LPD
remains unclear. However, these evidences explained the para-
neoplastic nature of AA as a collateral damage to hematopoietic
progenitor cell while launching immune attack toward occult
lymphoma cells.6 As occult lymphoma cells tolerate, escape im-
mune surveillance mainly via IST, and re-expand as clonal evolu-
tion, it might be more aggressive than de novo lymphoma cells.2
Reviewing the literature, we knew that in cases of AA, use of IST
should be cautious, as IST might accelerate occult lymphoma
C.-T. Chen et al. / Journal of Cancer Research and Practice 3 (2016) 132e135 135escaping immune surveillance and evolving as a refractory lym-
phoma. Second, in cases of AA and concomitant NHL, to choose
cytotoxic chemotherapy or IST is an art. Depending on the intensity
of immunogenic cytopenia and aggressiveness of NHL, physician
might decide which aims should be treated ﬁrst. In this case,
splenomegaly at her ﬁrst presentation is difﬁcult to prove it lym-
phoma. However, lately lymphadenopathy and worsening spleno-
megaly conﬁrmed lymphoma involvement. Her presentation of AA
might be an immunogenic prodrome of DLBCL rather than hyper-
splenism related. It should be noted that splenomegaly are not
features of aplastic anemia; such ﬁndings suggest an alternative
diagnosis such as a clonal myeloid or lymphoid disease,17 although
there has been a rare case report of splenomegaly associated with
AA.18 There is also a possibility that this patient had both aplastic
anemia and diffuse large B-cell lymphoma. Aplastic anemia was
refractory to steroid but responsive to rituximab.19,20 Medinger et al
described two cases of concomitant AA and NHL,6 one case of
multiple myeloma and concomitant AA. All of their hematopoiesis
failed recovery after short course of chemotherapy, despite all
attaining complete remission. The former two received ISTand allo-
HSCT respectively. Both restored hematopoiesis; the last one
receiving IST, having temporary recovery, but still died of aplasia
and infection. According to literature, hematopoiesis seldom re-
covers in cases of NHL with antecedent or concomitant AA despite
remission of lymphoma. Nevertheless, here we provided a case
report of DLBCL with initial presentation of AA. Hematopoiesis
recovered after ﬁrst cycle of chemotherapy, and later a successful
stem cell harvest after complete remission of lymphoma.
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